This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

IMRIS Receives Innovation In Medical Devices Award By MN Business Magazine

VISIUS iCT is latest leading edge technology for intraoperative imaging solutions

MINNEAPOLIS, Oct. 30, 2013 /PRNewswire/ - IMRIS Inc. (NASDAQ: IMRS; TSX: IM) ("IMRIS" or the "Company") announced that the company has received the 2013 Innovation in Medical Devices Award from Minnesota Business Magazine in recognition for significantly improving medical technology with the launch of its VISIUS ® iCT. The awards were announced Oct. 29 during a dinner ceremony at the Hyatt Regency Minneapolis.

"As the global leader in intraoperative image-guided solutions, we anticipate that VISIUS iCT will be an invaluable tool for spine and neurosurgery and trauma, just as our VISIUS iMRI is now for cranial and skull-base neurosurgery," said Jay D. Miller, IMRIS President and CEO. "IMRIS is delighted for this recognition after recently joining the Twin Cities business community which is at the heart of world-class medical device innovation." IMRIS relocated its operations to Minnetonka from Winnipeg in early 2013.

VISIUS iCT, the newest IMRIS product approved by the U.S. Food and Drug Administration in July, improves spinal and orthopaedic surgery by bringing state-of-the-art computed tomography (CT) imaging to the patient during procedures by mounting the scanner on ceiling rails that transport the scanner to the patient. Surgical precision and patient outcomes are improved when the surgeon has access to this high-quality imaging during the procedure. Other types of intraoperative X-ray based imaging on the market occupy valuable OR floor space and do not match the image resolution and applications available with VISIUS iCT.

Developed for the neurosurgery and spine surgery markets, VISIUS iCT also features advanced software applications that maximize image quality while minimizing radiation exposure in real time and industry leading post-processing software to enhance surgical diagnosis and intervention.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $95.03 -2.90%
FB $116.73 7.20%
GOOG $691.02 -2.10%
TSLA $247.54 -1.60%
YHOO $36.59 -0.97%


Chart of I:DJI
DOW 17,830.76 -210.79 -1.17%
S&P 500 2,075.81 -19.34 -0.92%
NASDAQ 4,805.2910 -57.85 -1.19%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs